Company

An innovative biotech company solving intractable disease and critical social challenges with AI and smart devices.

2026.05

Established

12

Patents filed (6 domestic · 6 PCT)

10+

Partner countries

1

JoongAng Innovative IT Award

CEO Message

A company that solves social problems with technology

BL

Brian Lee

Chief Executive Officer

I launched our Bio AI, smart device and AI agent businesses in the first half of 2025, driven by our inventions in smart glasses, AI and autonomous driving.

As Meta, Samsung, Google and Apple scale up smart-glasses investment, our focus is on solving critical social problems with smart glasses and AI: preventing drowsy-driving accidents and enabling early diagnosis of severe diseases.

GeniusMed will continue to grow so that each business we have launched bears strong results.

Executive Summary

Mission

Solving high-mortality disease

Solving high-mortality diseases and severe social problems with AI and smart technologies.

Core Business

Bio AI smart glasses R&D

Bio AI smart glasses R&D, plus bio and medical device sales and trade.

Technology

AI early diagnosis & autonomy

AI-based early disease diagnosis and agents, plus drowsy-driving prevention and autonomous-driving technology.

Market

Entering convergence markets

Entering the global IVD, smart glasses and autonomous-driving convergence markets.

Partners

Partners in 10+ countries

R&D, marketing and sales collaboration with partners across 10+ countries including Korea, Japan, China, Switzerland and Singapore.

IP Status

6 domestic · 6 PCT filings

Two filings for smart glasses and autonomous driving; two each for Bio AI diagnosis and AI agents.

Company History

2025.05

Filed 2 domestic patents: smart glasses, AI & autonomous driving

PCT international filing completed for both
2025.08

Filed 4 domestic patents: Bio AI diagnosis & AI agents

PCT international filing completed for all four
2025.08

Marketing partnership with Shanghai Upper Bio-Tech Pharma & Singapore BamX

Channels secured across China and ASEAN
2025.09

R&D partnership with IT Lab Co., Ltd., Japan

Joint development of IVD devices and biopharmaceuticals
2026.02

Joint R&D partnership with CSEM SA, Switzerland

Integrating vital-sign monitoring into smart glasses
2026.05

GeniusMed Co., Ltd. incorporated

Headquarters established in Bundang-gu, Seongnam
2026.08

JoongAng Ilbo 2026 H2 Innovative IT Grand Prize

Industrial Convergence & Smart Technology category

Awards

2026.08

2026 Innovative IT Award

The JoongAng Newspaper

Awarded in the Industrial Convergence & Smart Technology category for the innovation of our Bio AI smart glasses and drowsy-driving prevention technology.

Global R&D Collaboration

CSEM MoU & Eurostars joint proposal

A memorandum of understanding with Switzerland's CSEM was signed electronically on 2 July 2026 and is valid for two years. The parties jointly develop vital-sign monitoring — heart rate, HRV, SpO₂, blood pressure and EEG — integrated into smart glasses. GeniusMed leads the project and system integration; CSEM contributes optical sensing, biopotentials and digital-health R&D.

A joint proposal for the 11th Eurostars call is being prepared with CSEM (deadline 10 September 2026). If selected, the Korean SME is funded for up to 67% of project cost through the Korea Institute for Advancement of Technology, strengthening eligibility for global government R&D funding.

CSEM Profile

Founded: 1984
Researchers: 640+
Countries: 45
Headquarters: Neuchâtel, CH

CEO Brian Lee · Jens Krauss (VP MedTech BU, CSEM)

www.csem.ch

Roadmap & Targets

Growth Roadmap

2026

IP rights & global collaboration

Full patent filing for Bio AI diagnosis & AI agents
Joint Eurostars proposal with CSEM
Recruiting core talent

2027

Prototype & clinical validation

Target 95% AI diagnostic accuracy
First-generation integrated device prototype and medical-data AI
Clinical validation at SNU Bundang Hospital, Severance Hospital and Mayo Clinic

2028+

Global commercialization

PCT-based entry into the US, EU, China, Japan and India
Ramp-up of approvals, SaaS and licensing revenue
Groundwork for a technology-track IPO

Investment Proposal

Shape the future of healthcare and mobility with GeniusMed

Proprietary patents, a global partner network, a hybrid revenue model and entry into massive markets — four axes of growth.

Investor Enquiry Learn More

Patents Filed

6 + 6 PCT

Global Partners

10+

Business

Trade · License · SaaS

Investors

IVD · AR · Autonomy